MX2022006058A - Polimero de biomolecula multimerica multiespecifica multifuncional que tiene duracion prolongada in vivo. - Google Patents

Polimero de biomolecula multimerica multiespecifica multifuncional que tiene duracion prolongada in vivo.

Info

Publication number
MX2022006058A
MX2022006058A MX2022006058A MX2022006058A MX2022006058A MX 2022006058 A MX2022006058 A MX 2022006058A MX 2022006058 A MX2022006058 A MX 2022006058A MX 2022006058 A MX2022006058 A MX 2022006058A MX 2022006058 A MX2022006058 A MX 2022006058A
Authority
MX
Mexico
Prior art keywords
biomolecule
multifunctional
multispecific
polymer
present
Prior art date
Application number
MX2022006058A
Other languages
English (en)
Inventor
Sungjin Park
Daeseong Im
Ryuryun Kim
Minsum Kim
Jaeyoung Choi
Original Assignee
Onegene Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onegene Biotechnology Inc filed Critical Onegene Biotechnology Inc
Publication of MX2022006058A publication Critical patent/MX2022006058A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/104—Aminoacyltransferases (2.3.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01009—D-Xylulose reductase (1.1.1.9), i.e. xylitol dehydrogenase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01307—D-Xylose reductase (1.1.1.307)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
    • C12Y102/03—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with oxygen as acceptor (1.2.3)
    • C12Y102/03003—Pyruvate oxidase (1.2.3.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/02—Aminoacyltransferases (2.3.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y401/00—Carbon-carbon lyases (4.1)
    • C12Y401/01—Carboxy-lyases (4.1.1)
    • C12Y401/01003—Oxaloacetate decarboxylase (4.1.1.3)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

La presente invención se refiere a un polímero de biomolécula multimérico multiespecífico multifuncional que se forma obteniendo una biomolécula, a la que se une una etiqueta C-terminal de ubiquitina, mediante la expresión recombinante de la biomolécula a partir de una célula hospedadora, y poliubiquitinando, in vitro, la biomolécula junto con un sustrato y las proteínas E1 (enzima de activación), E2 (enzima de conjugación) y E3 (ligasa) que están involucradas en la ubiquitinación y, por lo tanto, la biomolécula se une a un andamiaje de poliubiquitina que se forma mediante la unión covalente de dos o más ubiquitinas. La biomolécula de la presente invención puede ser una o más seleccionadas del grupo que consiste de una proteína, péptido, polipéptido, anticuerpo, fragmento de anticuerpo, ADN y ARN y, por ejemplo, mediante el uso de proteínas heterólogas, se puede impartir funcionalidad modularizada al polímero de biomolécula multiespecífica multifuncional. Además, de conformidad con la presente invención, el polímero de biomolécula multimérico multiespecífico multifuncional se proporciona en una forma que se une a una molécula capaz de aumentar la duración in vivo y, por lo tanto, puede usarse para producir fármacos que requieren una mayor duración in vivo de la eficacia.
MX2022006058A 2019-11-27 2020-11-27 Polimero de biomolecula multimerica multiespecifica multifuncional que tiene duracion prolongada in vivo. MX2022006058A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20190154945 2019-11-27
PCT/KR2020/017029 WO2021107660A1 (ko) 2019-11-27 2020-11-27 생체 내 지속시간이 연장된 다기능성 다중특이적 멀티머 생체분자 중합체

Publications (1)

Publication Number Publication Date
MX2022006058A true MX2022006058A (es) 2022-07-27

Family

ID=75731250

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022006058A MX2022006058A (es) 2019-11-27 2020-11-27 Polimero de biomolecula multimerica multiespecifica multifuncional que tiene duracion prolongada in vivo.

Country Status (12)

Country Link
EP (1) EP4067373A4 (es)
JP (1) JP2023504790A (es)
KR (1) KR102243257B1 (es)
CN (1) CN115244071A (es)
AU (1) AU2020391285B2 (es)
BR (1) BR112022010445A2 (es)
CA (1) CA3158903A1 (es)
CO (1) CO2022007332A2 (es)
IL (1) IL293078A (es)
MX (1) MX2022006058A (es)
WO (1) WO2021107660A1 (es)
ZA (1) ZA202205789B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024019553A1 (ko) * 2022-07-19 2024-01-25 주식회사 유비프로틴 보툴리눔 독소 a형 경쇄 단백질의 반감기를 증가시키는 방법
CN116199750A (zh) * 2023-01-06 2023-06-02 吉林大学 一种核糖体蛋白s11及制备方法和在疫苗佐剂中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7354722B1 (en) * 1999-06-11 2008-04-08 Signal Pharmaceuticals Modulators of Smurf and BMP/TGFβ signaling pathways
JP2003535165A (ja) * 2000-05-30 2003-11-25 ビリディス バイオテック インコーポレイテッド ポリユビキチン系ヒドロゲルとその用途
KR20050050824A (ko) 2003-11-26 2005-06-01 세메스 주식회사 베이크 장치에서의 웨이퍼 안착 상태를 감지하여 인터락을제어하기 위한 시스템 및 그의 제어 방법
JP5358187B2 (ja) * 2005-12-15 2013-12-04 ジェネンテック， インコーポレイテッド ポリユビキチンを標的とする方法と組成物
WO2009009773A1 (en) * 2007-07-11 2009-01-15 The Johns Hopkins University Use of otubain enzyme to cleave lysine-48-linked polyubiquitin
CN102753569A (zh) * 2009-12-14 2012-10-24 塞尔蛋白质股份有限公司 对纤维连接蛋白额外结构域b具有特异结合活性的修饰的泛素蛋白
WO2012036551A1 (en) * 2010-09-15 2012-03-22 Stichting Het Nederlands Kankerinstituut Total chemical synthesis of ubiquitin, ubiquitin mutants and derivatives thereof
WO2013137920A1 (en) * 2012-03-16 2013-09-19 Genentech, Inc. Engineered conformationally-stabilized proteins
JP5543556B2 (ja) 2012-09-05 2014-07-09 京セラ株式会社 携帯電子機器
KR101911438B1 (ko) * 2012-10-31 2018-10-24 삼성전자주식회사 이중 특이 항원 결합 단백질 복합체 및 이중 특이 항체의 제조 방법
TWI569816B (zh) 2014-04-18 2017-02-11 林信湧 一種用於治療痛風之吸入式醫藥組成物及其備製方法
GB201710620D0 (en) * 2017-07-03 2017-08-16 Glaxosmithkline Intellectual Property Ltd Targeted protein degradation
KR20190135393A (ko) * 2018-05-28 2019-12-06 주식회사 원진바이오테크놀로지 폴리유비퀴틴 스캐폴드에 결합된 생체분자들의 선형 멀티머 중합체 및 이의 용도

Also Published As

Publication number Publication date
EP4067373A1 (en) 2022-10-05
CA3158903A1 (en) 2021-06-03
CN115244071A (zh) 2022-10-25
AU2020391285A1 (en) 2022-06-09
AU2020391285B2 (en) 2024-05-23
JP2023504790A (ja) 2023-02-07
CO2022007332A2 (es) 2022-08-30
EP4067373A4 (en) 2023-12-06
ZA202205789B (en) 2024-01-31
WO2021107660A1 (ko) 2021-06-03
BR112022010445A2 (pt) 2022-09-06
KR102243257B1 (ko) 2021-04-22
IL293078A (en) 2022-07-01

Similar Documents

Publication Publication Date Title
ZA202205789B (en) Multifunctional multispecific multimeric biomolecule polymer having prolonged in-vivo duration
Schlosser et al. Mapping of phosphorylation sites by a multi-protease approach with specific phosphopeptide enrichment and nanoLC− MS/MS analysis
Jennebach et al. Crosslinking-MS analysis reveals RNA polymerase I domain architecture and basis of rRNA cleavage
Spolaore et al. Local unfolding is required for the site-specific protein modification by transglutaminase
Passioura et al. Flexizyme‐Mediated Genetic Reprogramming As a Tool for Noncanonical Peptide Synthesis and Drug Discovery
Billing et al. Complementarity of SOMAscan to LC-MS/MS and RNA-seq for quantitative profiling of human embryonic and mesenchymal stem cells
WO2008140582A3 (en) Production of anti-microbial peptides
WO2009091912A3 (en) Improved mammalian expression vectors and uses thereof
EP2096174A1 (en) Ubiquitin binding polypeptides
WO2011146891A3 (en) High-affinity fully functional soluble single-domain human cd4, antibodies, and related fusion proteins
WO2008077945A3 (en) Anti-chemokine (ccl2, ccl3, ccl5, cxcl11, cxcl12) single-domain antibodies
WO2007077028A3 (en) Antibodies directed to her-3 and uses thereof
PL393647A1 (pl) Sposób wytwarzania polipeptydu w komórce gospodarza, przeciwciało, fragment przeciwciała, fuzja białkowa, kompozycja farmaceutyczna i sposób leczenia raka
WO2006116181A3 (en) Regulatory t cell mediator proteins and uses thereof
WO2008028977A3 (en) Serum albumin binding proteins with long half-lives
EP4223783A3 (en) Fc containing polypeptides with altered glycosylation and reduced effector function
WO2014080401A3 (en) Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides
HK1082761B (zh) 具有複製的條件起源的循壞dna分子，其製備方法及其在基因治療中的應用
WO2009097017A3 (en) Antibodies and fc fusion protein modifications with enhanced persistence or pharmacokinetic stability in vivo and methods of use thereof
WO2004024750A3 (en) Cd44-binding ligands
WO2022056254A3 (en) Dna modifying enzymes and active fragments and variants thereof and methods of use
WO2008131315A8 (en) Identification and method for using the pre-ligand assembly domain of the il-17 receptor
WO2012126118A8 (en) Polypeptides with affinity for heat shock proteins (hsps) and hsp associated complexes (hacs) and their use in diagnosis and therapy
Zhang et al. Sortase A‐mediated synthesis of ligand‐grafted cyclized peptides for modulating a model protein‐protein interaction
VanDyke et al. Biologics-based degraders—an expanding toolkit for targeted-protein degradation